THROMBOCYTHEMIA MYELOFIBROSIS Clinical Trials

6 clinical trials for THROMBOCYTHEMIA MYELOFIBROSIS across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) — RECRUITING
• A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE ACTIVITY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC, ANEMIC SUBJECTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA (PV) MYELOFIBROSIS, OR POST ESSENTIAL THROMBOCYTHEMIA (ET) MYELOFIBROSIS WHO WERE PREVIOUSLY TREATED WITH JAK INHIBITOR THERAPY — RECRUITING · PHASE3
• A RANDOMIZED CONTROLLED PHASE 3 STUDY OF ORAL PACRITINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH THROMBOCYTOPENIA AND PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS. — RECRUITING · PHASE3
• Managed Access Programs for INC424, Ruxolitinib — OTHER
• OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF MOMELOTINIB IN SUBJECTS WITH PRIMARY MYELOFIBROSIS, POST POLYCYTHEMIA VERA MYELOFIBROSIS, POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS, POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA — COMPLETED
• A PHASE 2, OPEN-LABEL, PROSPECTIVE STUDY OF PRM-151 IN SUBJECTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (POST-PV MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MF (POST-ET MF) — COMPLETED · PHASE2

Refine this search